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Abstract – Background: Restless legs syndrome (RLS) is a sensory motor disorder characterized by a distressing 
urge to move the legs and sometimes also other parts of the body usually accompanied by a marked sense 
of discomfort or pain in the leg or other affected body part. Many treatments have been used to minimize 
the discomfort of the disease, among them the anticonvulsant therapy.  Aim: This review aims to evaluate 
the efficacy and safety of anticonvulsant treatment for idiopathic RLS.  Method: Systematic review of 
randomized or quasi-randomized, double blind trials on anticonvulsant treatment for RLS. Outcomes: relief 
of RLS symptoms, subjective and objective sleep quality, quality of life, and adverse events associated with 
the treatments.  Results: A total of 231 patients were randomized in three cross over studies and one parallel 
study. Three studies with carbamazepine, one with sodium valproate, and one with gabapentin, and they were 
very heterogeneous so we could not perform a metanalyses.  Conclusions: There is no scientific evidence on 
RLS treatment with anticonvulsants for clinical practice. 
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Anticonvulsivantes para a síndrome das pernas inquietas idiopática: revisão sistemática
Resumo – Contexto: A síndrome das pernas inquietas (SPI ) é uma desordem caracterizada por um impulso 
de mover as pernas e as vezes outras partes do corpo acompanhado geralmente por desconforto ou da dor 
nas pernas ou em outra parte afetada. Muitos tratamentos tem sido utilizados para aliviar o desconforto 
causado pela doença entre eles os anticonvulsivantes.  Objetivo: Este estudo objetivou avaliar a eficácia e 
segurança do tratamento da SPI com as drogas anticonvulsivantes.  Método: Revisão sistemática de ensaios 
clínicos randomizados ou quasi-randomizados, duplo-cegos para o tratamento com anticonvulsivantes para 
SPI. Desfechos: alívio dos sintomas da SPI, qualidade subjetiva e objetiva do sono, qualidade de vida e efeitos 
adversos relacionados ao tratamento.  Resultados: Um total de 231 pacientes foram randomizados em três 
estudos cross-over e um estudo paralelo. Três estudos avaliaram a carbamazepina, um estudo avaliou o ácido 
valpróico e o outro a gabapentina, eles eram muito heterogêneos, o que impossibilitou a metanálise dos 
resultados.  Conclusão: Não existe evidência científica, que o tratamento da SPI com anticonvulsivantes é 
eficaz e seguro, para a prática clínica. 
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Restless legs syndrome (RLS) is a sensory motor disor-
der characterized by a distressing urge to move the legs 
and sometimes also other part of the body usually ac-
companied by a marked sense of discomfort or pain in 
the leg or other affected body part1. The prevalence of 
RLS is estimated to be 5% to 15% in adults and it is more 
common in women2,3, and was firstly reported in Brazil 
by Mattos Pimenta4. RLS may be either idiopathic (pri-
mary RLS, which often has a familial component) or sec-
ondary, occurring with other medical conditions, partic-
ularly iron deficiency anaemia, pregnancy, or end-stage 
renal disease5. 
The most common pharmacological agents used in 
clinical practice for the treatment of RLS are levodopa, 
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dopamine agonists, opioids, benzodiazepines and anticon-
vulsants1,6. Anticonvulsants are generally structural ana-
logues of g-aminobutiric acid (GABA) but in many cases 
the precise receptor(s) and biochemical function still re-
main unknown. It is suggested that novel receptor bind-
ing sites and an accumulation of GABA in different regions 
of the brain might be responsible for its effects in RLS7. 
Its psychotropic and analgesics effects may be exerted, at 
least indirectly, through other neurotransmitters. In vivo 
the gabapentin antagonizes 3,4-diamopyridine-induced 
release of dopamine, nor-epinefrine and serotonin in the 
rat hippocampus, mesolimbic and striatal regions. These 
neurotransmitters, and in particular dopamine, are prob-
ably involved in the pathophysiology of RLS7-9.
Although anticonvulsants seems especially useful for 
treating mild to moderate RLS, particularly in patients re-
porting pain, the effectiveness of this class of drugs in the 
treatment of RLS is still controversial. In this clinical set-
ting was relevant to conduct a systematic review to eval-
uate the clinical benefit of anticonvulsants for RLS.
method
Inclusion criteria
Study design: Parallel and cross-over randomized and quasi-
randomized controlled trials; Participants: Patients who meet any 
clinical criteria for idiopathic RLS10,11; Exclusion criteria: Studies with 
secondary form of RLS such as metabolic, neuropathic or renal 
disease; Types of interventions: All anticonvulsants drugs used for 
treatment of RLS; Comparison groups include: Placebo; no interven-
tion and other category of drugs; Outcomes measures: Relief of RLS 
symptoms as measured by the International RLS Study Group 
Rating Scale for RLS (IRLSSG Rating Scale) was the primary out-
come12. Secondary outcomes were adverse events associated 
with the treatments (including augmentation); subjective sleep 
quality (any description about sleep quality, i.e., feeling like well-
being, tiredness reduction); objective sleep quality measured by 
night polissomnografy (sleep efficiency, total sleep time, arousal 
index, PLMS index). The ethics committee of Universidade Fed-
eral de São Paulo/hospital São Paulo approved the study.
The electronic search
The search strategies were run on December 2007 using the 
following terms and their synonymous: restless legs syndrome, 
Ekbom syndrome, periodic leg movement, periodic limb move-
ment, PLM, PLMS, PLMD, sindrome de las piernas inquietas, sín-
drome das pernas inquietas, sindrome delle gambe senza riposo, 
syndrome des jambs sans repos, idiopathischen restless-legs-
syndrom. The search for trials was carried out through The co-
chrane Library, Medline, Pubmed, Lilacs, Embase and Scielo. Be-
sides the most traditional electronic databases, other sources 
were also considered: thesis indexed at BIREME/PAhO-WhO 
(Biblioteca Regional Medicina/Panamerican health Organiza-
tion of the World health Organization); reference list of all re-
covered trials; additional information asked for the authors of 
primary studies by electronic mail.
Methodological quality of included studies
The studies were judged according to cochrane handbook 
based on allocation concealment (randomization), blinding (per-
formance and detection bias), and attrition bias. 
Data analysis
Data synthesis and analysis was performed using the co-
chrane Review Manager software, RevMan version 4.2.8. Dichot-
omous data (adverse events) were expressed as relative risk (RR). 
Weighted mean difference (WMD) was used when continuous 
data were available from included studies. We included cross-
over study designs if the reported results had their within-pa-
tients variation, as given by paired tests13. For both dichotomous 
and continuous data, we used 95% confidence intervals (cI). The 
statistical analysis using random effect model14 was used to es-
timate the treatment effects as compared to placebo. Statis-
tical significance was considered when p<0.05. heterogeneity 
between estimated effects across studies was analyzed using 
the inconsistency test (I2), which describes the percentage of 
the variability in effect estimates due to heterogeneity rath-
er than sampling error15. Statistical heterogeneity was assumed 
in case I2>50%. According to the type of information available 
in the articles or by contacting the authors of primary studies, 
the results were pooled based on either endpoint or change 
from baseline as well as on subcategories of medication and 
time length of treatment.
results
We identified 1028 studies related to pharmacologi-
cal treatment for RLS, among them eleven trials published 
related to anticonvulsant therapy. Four randomized clin-
ical trials in English were included in this review for they 
fulfilled the inclusion criteria (Table 1). Seven trials were 
excluded (Table 2), six trials were not randomized ones 
(open-label), and one trial was excluded because it was a 
duplicated published.
A total of 231 patients were randomized in crossover 
and parallel design studies. Fifty patients were random-
ized in crossover studies (6 patients received carbamaze-
pine, 20 received valproic acid, and 24 received gabap-
entin), and out of 181 patients were randomized in the 
parallel-arm trial (84 received carbamazepine, and 90 re-
ceived placebo). 
We found several subjective measures (visual analogue 
scales, patients global impression, clinical global impres-
sion, Pittsburg sleep quality index, IRLSSG rating scale) and 
objective measures (polysomnographic measures) used in 
these studies such as describe below. 
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Borregueiro16
IRLSSG rating scale – The patients with gabapentin com-
pared to placebo reported that had a greater decrease 
in IRLSSG rating scale (WMD: –8.40; 95% cI –12.00 to 
–4.80; p<0.001);
Patients global impression – There was no improvement in 
the scores of patients global impression (WMD: 20.5; 95% 
cI 13.30 to 27.70; p<0.0001);
Clinical global impression – There was a lower and not sta-
tistically significant improvement in the scores of clini-
cal global impression (WMD: –1.10; 95% cI –1.93 to –0.27; 
p<0.01);
Pittsburg sleep quality index – There was a lower im-
provement in sleep quality (WMD: –2.90; 95% Ic –4.01 to 
–1.79; p<0.001);
Visual analogue scale – The results were not statistically 
significant (p=NS);
Polissomnographic measures – The patients with gabapen-
tin compared to placebo reported a reduced PLMI (WMD: 
–9.70; 95% cI –18.84 to –0.56; p<0.05), showed a not sta-
tistical significant improvement of PLMAI (WMD: –1.10; 
95%cI –4.70 to 2.50; p=NS), increased the total sleep time 
(WMD: –0.50; 95% cI –0.77 to –0.23; p=0.01), sleep effi-
ciency (WMD: –9.80; 95% cI –13.95 to –5.65; p<0.0001), 
stage 1 (WMD: –22.80; 95% cI –41.92 to –3.68; p<0.05), 
and slow wave sleep (WMD: –22.30; 95% cI –42.25 to –
2.35; p<0.05). The others measures, sleep latency (p=NS), 
stage 2 (p=NS), REM stage (p=NS), REM sleep latency 
(p=NS), and arousal index (p=NS) were not statistically 
significant (*NS= no significant).
Adverse events – The side effects occur in 48% of pa-
tients taking gabapentin, malaise and abdominal pain 
were the most common. No cases of augmentation phe-
nomenon were described.
Telstald17
Subjective measures – In subjective analyses reported by 
patients both placebo and carbamazepine decreased the 
Table 1. Characteristics of the trials included in this review.
Study Allocation 
concealment
Method Participants Interventions Outcomes
Borregueiro
2002
A Double-blind, 
randomized, 
placebo-controlled, 
crossover study
N=24, RLS/ 
IRLSSG, aged 33-
75 years. clinical 
criteria IRLSSG
Gabapentin (600/2400 
mg per day) or placebo, 
during 3 weeks each 
period, 1 week washout
Rls rating scale, patients 
global impression, clinical  
global impression of change, 
poli-somnographic measures
Telstald 
1984
B Randomized, 
placebo-controlled, 
parallel study
N=181, RLS 
clinical criteria, 
122 F, 52M, aged 
17-86 years
carbamazepine (100/300 
mg per day) or placebo, at 
bed time, during 5 weeks
Subjective measures, analog 
scale for symptom severity 
and symptom improvement; 
number of attacks per week
Lundval 
1983
B Randomized, 
placebo-controled, 
crossover study
N=6, RLS clinical 
criteria,2 female, 
4 male, aged 
37-71 years
carbamazepine (200/600 
mg per day) or placebo, 
during 14 days each 
period, no washout 
period was mentioned
Subjective measures: daily  
rating of attacks of: 1) RLS  
sensations per day and 
number of days with 
attacks; 2) severity of RLS 
and patients preference for 
drug or placebo or neither 
for further treatment
Eisensehr 
2004
A Double-blind, 
randomized, 
placebo-controlled, 
crossover study
N=20, RLS/ 
IRLSSG,12 female, 
8 male, aged 
41-79 years
Slow release valproic acid 
(300/600 mg), levodopa 
/benzerazid 100/25-
200/50 mg), or placebo at 
bedtime, during 3 weeks  
each period, without 
washout period
RLS rating scale,  
poli-somnographic  
measures
Table 2. Characteristics of the trials excluded in this review.
Study Reason for exclusion
Adler20 1997 Open label 
Bravo21 2004 Open label 
happe22 2001 Open label 
happe23 2003 Open label 
Youssef24 2004 Open label
Zucconi25 1989 Open label 
Sorensen26 1984 Duplicated study
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number of attacks, but carbamazepine was more effec-
tive than placebo (p=0.02). 
Adverse events – The side effects were not described in 
these study and seven drop outs were described (reason 
not related to the treatment).
Lundval18
Subjective measures - The study reported in subjective 
measures improvement in 50% of patients, and other 50% 
reported insufficient improvement. No statistical analy-
ses were performed in this study. 
Adverse events – The side effects reported were mild 
gastritis, sweating, dizziness and vomiting and two drop 
outs were described (reason by the lack of the effect of 
carbamazepine).
Eisensehr19
Subjective measures – Slow-release valproic acid signifi-
cantly decreased the subjectively rated intensity of RLS 
complaints (WMD: –1.70; 95% cI –3.02 to -0.38, p=0.022) 
and duration of symptoms (WMD: –92.30; 95% cI –231.76 
to 47.06; p=0.007) compared to placebo. 
Polissomnographic measures – Total sleep time (p=NS), 
wake after sleep onset (p=NS), PLMAI (p=NS), stage 1 
(p=NS), stage 2 (p=NS), stage3/4 (p=NS), stage REM (p=NS), 
PLMI (p=NS), and arousal index (p=NS) were not statisti-
cally significant. 
Adverse events – The side effects headache, drowsiness, 
and difficulties falling asleep were the most common ad-
verse events and there were no drop outs.
discussion
Overall the methodological quality of the studies was 
considered as adequate (A) in two studies (Borregueiro16; 
Eisensehr19), and unclear (B) in the others two studies (Tel-
stald17; Lundval18). On the other hand, almost all included 
studies were classified as “low risk” of systematic error, ac-
cording to methodological quality of included studies.
The methodological quality of the carbamazepine in-
cluded studies (Telstald17; Lundval18) was considered poor, 
where data and methods reported in these articles were 
not described by the authors with sufficient details, even 
after contact by e-mail we also could not retrieve further 
information from the authors. however the studies about 
slow-release valproic acid (Eisensehr19) and gabapentin 
(Borregueiro16) showed good methodological quality and 
the results for continuous outcome measures were satis-
factory. But their short-term follow up, which ranged from 
three to twelve weeks, was not possible to estimate the 
efficacy of treatment before doing long-term evaluations. 
It may be a source of bias that different treatment se-
quences were not separated by washout periods. howev-
er, in Eisensehr19 study outcome variables were measured 
at the end of each treatment sequence, when (based on 
the half lives of the drugs) there was probably no effect 
of the drug taken before. A washout period was present 
in Borregueiro16 study, the one week washout period was 
probably based on the half life of the drug either, but 
there is no evidence that its clinical action is short-lasting, 
and its duration seems not sufficient to avoid a carry over 
effect of gabapentin. 
Overall, the drugs were well-tolerated, except in Bor-
regueiro16 study, when 48% of patients had side effects 
taking gabapentin but no patients dropped out because 
of them.
Augmentation syndrome, which consists of an ab-
normally severe pattern of RLS, is a common reason for 
changing medications27 and an important clinical problem 
noted on other therapies, such as levodopa and dopami-
nergic agonists. It is important to note that no cases of 
augmentation were reported with anticonvulsant therapy 
in a short-term follow up. The present reviewers advise 
physicians who are in charge of treatment for RLS patients 
to be aware of the augmentation syndrome in a long-term 
follow up. 
There is no evidence that pharmacological treatment 
for RLS with anticonvulsant is effective and safe. Future 
trials should follow internationally published guidelines 
for reporting trials. Well designed randomized clinical tri-
als are needed to assess the efficacy and safety of antic-
ovulsant therapy for Restless legs syndrome. 
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